Naxitamab for Relapsed/Refractory Neuroblastoma
Journal of Pediatric Oncology Nursing
Published online on February 19, 2026
Abstract
Journal of Pediatric Hematology/Oncology Nursing, Volume 43, Issue 3, Page 189-197, May/June 2026.
BackgroundChildren with relapsed/refractory (R/R) neuroblastoma are at risk for poor outcomes due to resistant disease. Naxitamab is an anti-glycolipid disialoganglioside (GD2) monoclonal antibody approved by the Food and Drug Administration for the ...
BackgroundChildren with relapsed/refractory (R/R) neuroblastoma are at risk for poor outcomes due to resistant disease. Naxitamab is an anti-glycolipid disialoganglioside (GD2) monoclonal antibody approved by the Food and Drug Administration for the ...